rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IPHA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Why is Innate Pharma stock sliding today?
      11h agoInvesting.comIPHA
      Innate Pharma stock tumbles after phase 1 trial data
      12h agoInvesting.comIPHA
      Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026
      21h agoYahoo FinanceIPHA
      Innate Pharma stock maintained at Buy by BTIG on pipeline progress
      Nov 5Investing.comIPHA
      Innate Pharma Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceIPHA
      Innate Pharma Reports Third Quarter 2026 Business and Financial Update
      Nov 5Yahoo FinanceIPHA
      Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
      Oct 8Yahoo FinanceIPHA
      Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

      Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

      Sep 23Yahoo FinanceIPHA
      Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

      Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier. The closing triggered a $75 million upfront payment. Management projects funding through the end of the first quarter of 2028, including the partnership payment and a completed equity financing […]

      Sep 23Yahoo FinanceIPHA
      Innate Pharma stock maintained at Buy by H.C. Wainwright
      Sep 21Investing.comIPHA
      Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Sep 18The Globe and MailIPHA
      Innate Pharma Q2 Earnings Call Highlights

      Innate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab. Chief Executive Officer Jonathan

      Sep 17Yahoo FinanceIPHA
      Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip
      Sep 17Investing.comIPHA
      Innate Pharma H1 2026 Earnings Call Transcript
      Sep 17BenzingaIPHA
      Earnings Scheduled For September 17, 2026
      Sep 17BenzingaIPHAYI
      Innate Pharma Reports First Half 2026 Business Update and Financial Results

      MARSEILLE, France, September 17, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release.

      Sep 17Yahoo FinanceIPHA
      Innate Pharma, Grove, and more set to report earnings Thursday
      Sep 17Investing.comIPHA
      Sobi and Innate announce partnership is now effective following completion of closing conditions
      Sep 17Yahoo FinanceIPHA
      Innate Pharma closes Sobi partnership, receives $75m upfront
      Sep 16Investing.comIPHA
      Innate Pharma, Sobi Partnership Becomes Effective
      Sep 16Yahoo FinanceIPHA
      Innate Pharma at H.C. Wainwright conference: narrower pipeline, bigger bets
      Sep 14Investing.comIPHA
      Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

      MARSEILLE, France, September 10, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026.

      Sep 10Yahoo FinanceIPHA
      Innate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment Conference

      Detailed price information for Innate Pharma (IPHYF) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailIPHA
      Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      MARSEILLE, France, September 02, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference:

      Sep 2Yahoo FinanceIPHA

      This is the newest page. Registered accounts read further back.